Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects.
Identifieur interne : 001B76 ( Main/Corpus ); précédent : 001B75; suivant : 001B77Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects.
Auteurs : Josée Savard ; Sébastien Simard ; Isabelle Giguère ; Hans Ivers ; Charles M. Morin ; Elizabeth Maunsell ; Pierre Gagnon ; Jean Robert ; Danièle MarceauSource :
- Palliative & supportive care [ 1478-9515 ] ; 2006.
English descriptors
- KwdEn :
- Breast Neoplasms (immunology), Breast Neoplasms (pathology), Breast Neoplasms (psychology), Cognitive Behavioral Therapy (methods), Cytokines (metabolism), Data Interpretation, Statistical (MeSH), Depression (etiology), Depression (immunology), Depression (therapy), Female (MeSH), Humans (MeSH), Killer Cells, Natural (immunology), Lymphocytes (immunology), Middle Aged (MeSH), Neoplasm Metastasis (immunology), Psychiatric Status Rating Scales (MeSH), Time Factors (MeSH), Treatment Outcome (MeSH), Waiting Lists (MeSH).
- MESH :
- chemical , metabolism : Cytokines.
- etiology : Depression.
- immunology : Breast Neoplasms, Depression, Killer Cells, Natural, Lymphocytes, Neoplasm Metastasis.
- methods : Cognitive Behavioral Therapy.
- pathology : Breast Neoplasms.
- psychology : Breast Neoplasms.
- therapy : Depression.
- Data Interpretation, Statistical, Female, Humans, Middle Aged, Psychiatric Status Rating Scales, Time Factors, Treatment Outcome, Waiting Lists.
Abstract
OBJECTIVE
Depression is particularly prevalent in patients with advanced cancer. Cognitive therapy (CT) is an empirically supported treatment for depression in the general population. However, efficacy remains to be demonstrated in patients with advanced cancer. A prior controlled trial of CT in a group format showed improvements in depression, mood disturbance, and self-esteem; however, these effects were not maintained over time. Studies examining the efficacy of individual format CT interventions that may ensure more long-term maintenance of benefits are necessary. This study assessed the efficacy of CT for depression administered individually in women with metastatic breast cancer and its effect on immune function.
METHOD
Forty-five women were randomly assigned to either individual CT or to a waiting-list control (WLC) condition. CT was composed of eight weekly sessions of CT and three booster sessions administered at 3-week intervals following the end of treatment.
RESULTS
Patients treated with CT had significantly lower scores on the Hamilton Depression Rating Scale at posttreatment compared to untreated patients. Pooled data from both groups indicated significant reductions of depressive symptoms from pre- to posttreatment, as well as reduction of associated symptoms including anxiety, fatigue, and insomnia symptoms. These effects were well sustained at the 3- and 6-month follow-up evaluations. CT for depression did not appear to have a significant impact on immune functioning.
SIGNIFICANCE OF RESULTS
Findings of this study support the efficacy of CT for depression in this population and suggest that the administration of individual and booster sessions after treatment termination may be instrumental in sustaining the treatment effects over time.
DOI: 10.1017/s1478951506060305
PubMed: 17066964
Links to Exploration step
pubmed:17066964Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects.</title><author><name sortKey="Savard, Josee" sort="Savard, Josee" uniqKey="Savard J" first="Josée" last="Savard">Josée Savard</name><affiliation><nlm:affiliation>Laval University Cancer Research Center, Université Laval, Québec, Québec, Canada. josee.savard@psy.ulaval.ca</nlm:affiliation></affiliation></author><author><name sortKey="Simard, Sebastien" sort="Simard, Sebastien" uniqKey="Simard S" first="Sébastien" last="Simard">Sébastien Simard</name></author><author><name sortKey="Giguere, Isabelle" sort="Giguere, Isabelle" uniqKey="Giguere I" first="Isabelle" last="Giguère">Isabelle Giguère</name></author><author><name sortKey="Ivers, Hans" sort="Ivers, Hans" uniqKey="Ivers H" first="Hans" last="Ivers">Hans Ivers</name></author><author><name sortKey="Morin, Charles M" sort="Morin, Charles M" uniqKey="Morin C" first="Charles M" last="Morin">Charles M. Morin</name></author><author><name sortKey="Maunsell, Elizabeth" sort="Maunsell, Elizabeth" uniqKey="Maunsell E" first="Elizabeth" last="Maunsell">Elizabeth Maunsell</name></author><author><name sortKey="Gagnon, Pierre" sort="Gagnon, Pierre" uniqKey="Gagnon P" first="Pierre" last="Gagnon">Pierre Gagnon</name></author><author><name sortKey="Robert, Jean" sort="Robert, Jean" uniqKey="Robert J" first="Jean" last="Robert">Jean Robert</name></author><author><name sortKey="Marceau, Daniele" sort="Marceau, Daniele" uniqKey="Marceau D" first="Danièle" last="Marceau">Danièle Marceau</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:17066964</idno><idno type="pmid">17066964</idno><idno type="doi">10.1017/s1478951506060305</idno><idno type="wicri:Area/Main/Corpus">001B76</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001B76</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects.</title><author><name sortKey="Savard, Josee" sort="Savard, Josee" uniqKey="Savard J" first="Josée" last="Savard">Josée Savard</name><affiliation><nlm:affiliation>Laval University Cancer Research Center, Université Laval, Québec, Québec, Canada. josee.savard@psy.ulaval.ca</nlm:affiliation></affiliation></author><author><name sortKey="Simard, Sebastien" sort="Simard, Sebastien" uniqKey="Simard S" first="Sébastien" last="Simard">Sébastien Simard</name></author><author><name sortKey="Giguere, Isabelle" sort="Giguere, Isabelle" uniqKey="Giguere I" first="Isabelle" last="Giguère">Isabelle Giguère</name></author><author><name sortKey="Ivers, Hans" sort="Ivers, Hans" uniqKey="Ivers H" first="Hans" last="Ivers">Hans Ivers</name></author><author><name sortKey="Morin, Charles M" sort="Morin, Charles M" uniqKey="Morin C" first="Charles M" last="Morin">Charles M. Morin</name></author><author><name sortKey="Maunsell, Elizabeth" sort="Maunsell, Elizabeth" uniqKey="Maunsell E" first="Elizabeth" last="Maunsell">Elizabeth Maunsell</name></author><author><name sortKey="Gagnon, Pierre" sort="Gagnon, Pierre" uniqKey="Gagnon P" first="Pierre" last="Gagnon">Pierre Gagnon</name></author><author><name sortKey="Robert, Jean" sort="Robert, Jean" uniqKey="Robert J" first="Jean" last="Robert">Jean Robert</name></author><author><name sortKey="Marceau, Daniele" sort="Marceau, Daniele" uniqKey="Marceau D" first="Danièle" last="Marceau">Danièle Marceau</name></author></analytic><series><title level="j">Palliative & supportive care</title><idno type="ISSN">1478-9515</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Breast Neoplasms (immunology)</term><term>Breast Neoplasms (pathology)</term><term>Breast Neoplasms (psychology)</term><term>Cognitive Behavioral Therapy (methods)</term><term>Cytokines (metabolism)</term><term>Data Interpretation, Statistical (MeSH)</term><term>Depression (etiology)</term><term>Depression (immunology)</term><term>Depression (therapy)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Killer Cells, Natural (immunology)</term><term>Lymphocytes (immunology)</term><term>Middle Aged (MeSH)</term><term>Neoplasm Metastasis (immunology)</term><term>Psychiatric Status Rating Scales (MeSH)</term><term>Time Factors (MeSH)</term><term>Treatment Outcome (MeSH)</term><term>Waiting Lists (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cytokines</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Depression</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Breast Neoplasms</term><term>Depression</term><term>Killer Cells, Natural</term><term>Lymphocytes</term><term>Neoplasm Metastasis</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Cognitive Behavioral Therapy</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Depression</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Data Interpretation, Statistical</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Psychiatric Status Rating Scales</term><term>Time Factors</term><term>Treatment Outcome</term><term>Waiting Lists</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>Depression is particularly prevalent in patients with advanced cancer. Cognitive therapy (CT) is an empirically supported treatment for depression in the general population. However, efficacy remains to be demonstrated in patients with advanced cancer. A prior controlled trial of CT in a group format showed improvements in depression, mood disturbance, and self-esteem; however, these effects were not maintained over time. Studies examining the efficacy of individual format CT interventions that may ensure more long-term maintenance of benefits are necessary. This study assessed the efficacy of CT for depression administered individually in women with metastatic breast cancer and its effect on immune function.</p></div><div type="abstract" xml:lang="en"><p><b>METHOD</b></p><p>Forty-five women were randomly assigned to either individual CT or to a waiting-list control (WLC) condition. CT was composed of eight weekly sessions of CT and three booster sessions administered at 3-week intervals following the end of treatment.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Patients treated with CT had significantly lower scores on the Hamilton Depression Rating Scale at posttreatment compared to untreated patients. Pooled data from both groups indicated significant reductions of depressive symptoms from pre- to posttreatment, as well as reduction of associated symptoms including anxiety, fatigue, and insomnia symptoms. These effects were well sustained at the 3- and 6-month follow-up evaluations. CT for depression did not appear to have a significant impact on immune functioning.</p></div><div type="abstract" xml:lang="en"><p><b>SIGNIFICANCE OF RESULTS</b></p><p>Findings of this study support the efficacy of CT for depression in this population and suggest that the administration of individual and booster sessions after treatment termination may be instrumental in sustaining the treatment effects over time.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17066964</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1478-9515</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Palliative & supportive care</Title><ISOAbbreviation>Palliat Support Care</ISOAbbreviation></Journal><ArticleTitle>Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects.</ArticleTitle><Pagination><MedlinePgn>219-37</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Depression is particularly prevalent in patients with advanced cancer. Cognitive therapy (CT) is an empirically supported treatment for depression in the general population. However, efficacy remains to be demonstrated in patients with advanced cancer. A prior controlled trial of CT in a group format showed improvements in depression, mood disturbance, and self-esteem; however, these effects were not maintained over time. Studies examining the efficacy of individual format CT interventions that may ensure more long-term maintenance of benefits are necessary. This study assessed the efficacy of CT for depression administered individually in women with metastatic breast cancer and its effect on immune function.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Forty-five women were randomly assigned to either individual CT or to a waiting-list control (WLC) condition. CT was composed of eight weekly sessions of CT and three booster sessions administered at 3-week intervals following the end of treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients treated with CT had significantly lower scores on the Hamilton Depression Rating Scale at posttreatment compared to untreated patients. Pooled data from both groups indicated significant reductions of depressive symptoms from pre- to posttreatment, as well as reduction of associated symptoms including anxiety, fatigue, and insomnia symptoms. These effects were well sustained at the 3- and 6-month follow-up evaluations. CT for depression did not appear to have a significant impact on immune functioning.</AbstractText><AbstractText Label="SIGNIFICANCE OF RESULTS" NlmCategory="CONCLUSIONS">Findings of this study support the efficacy of CT for depression in this population and suggest that the administration of individual and booster sessions after treatment termination may be instrumental in sustaining the treatment effects over time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Savard</LastName><ForeName>Josée</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laval University Cancer Research Center, Université Laval, Québec, Québec, Canada. josee.savard@psy.ulaval.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simard</LastName><ForeName>Sébastien</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Giguère</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Ivers</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Morin</LastName><ForeName>Charles M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Maunsell</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Gagnon</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Marceau</LastName><ForeName>Danièle</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Palliat Support Care</MedlineTA><NlmUniqueID>101232529</NlmUniqueID><ISSNLinking>1478-9515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014850" MajorTopicYN="N">Waiting Lists</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17066964</ArticleId><ArticleId IdType="doi">10.1017/s1478951506060305</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B76 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001B76 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= AutomedicationFrancoV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:17066964
|texte= Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:17066964" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AutomedicationFrancoV1
| This area was generated with Dilib version V0.6.38. |  |